In the following video, Motley Fool health care analyst David Williamson talks about Pfizer's (PFE 0.16%) earnings report. He details how the company managed to cut costs and shore up emerging market sales -- leading to it beating expectations this quarter -- despite the loss of patent protection for its cardiovascular disease prevention drug Lipitor, which was once the greatest-selling drug of all time.
Foolish Review: Pfizer Earnings
By Dave Williamson – Jan 29, 2013 at 7:44PM
NYSE: PFE
Pfizer
Market Cap
$139B
Today's Change
(-0.16%) $0.04
Current Price
$24.39
Price as of November 10, 2025 at 4:00 PM ET
Pfizer's surprising upside, even without Lipitor.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid